PMID- 31096438
OWN - NLM
STAT- MEDLINE
DCOM- 20190528
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 20
DP  - 2019 May
TI  - Efficacy and safety of perioperative appliance of sunitinib in patients with 
      metastatic or advanced renal cell carcinoma: A systematic review and 
      meta-analysis.
PG  - e15424
LID - 10.1097/MD.0000000000015424 [doi]
LID - e15424
AB  - BACKGROUND: The aim of this systematic review and meta-analysis is to 
      comprehensively evaluate the efficacy and safety of the perioperative use of 
      sunitinib in patients with metastatic and advanced renal cell carcinoma (RCC). 
      MATERIALS AND METHODS: We searched authenticated databases for related clinical 
      studies. The baseline characteristics, parameters concerning the efficacy and 
      safety of the perioperative use of sunitinib were extracted for subsequent 
      comprehensive analysis. The parameters which reflected the efficacy and safety as 
      overall survival (OS), progression-free survival (PFS), occurrence rate of 
      all-grade and grade >/=3 adverse effects (AEs) were carefully pooled using 
      comprehensive meta-analysis. RESULTS: We finally recruited 411 patients from 14 
      eligible studies. We found proteinuria (75.0%, 95% CI 62.1%-84.6%), anemia 
      (71.6%, 95% CI 60.9%-80.3%), athesia (60.0%, 95% CI 40.3%-77.0%), pause symptoms 
      (59.2%, 95% CI 49.2%-68.4%), arterial hypertension (53.1%, 95% CI 43.2%-62.7%), 
      and thrombocytopenia (52.5%, 95% CI 44.8%-60.0%) to be the most common all-grade 
      AEs. And arterial hypertension, athesia, cutaneous toxicity, hypophosphatemia, 
      leukopenia, pain, pause syndrome, renal dysfunction, and thrombocytopenia were 
      the most common types of grade >/=3 AEs. In addition, objective response rate (ORR) 
      of sunitinib to both the original and metastatic tumor sites increased with the 
      use of sunitinib, so did the OS and PFS. CONCLUSION: Common all-grade and grade 
      >/=3 AEs were carefully monitored. The perioperative use of sunitinib showed 
      superior ORR, OS, and PFS rates. Nevertheless, more studies are required to 
      further verify these findings.
FAU - Jin, Hongyu
AU  - Jin H
AD  - Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, 
      West China Hospital.
AD  - West China School of Medicine.
AD  - Department of Liver Surgery, Liver Transplantation Center, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, 
      West China Hospital.
AD  - West China School of Medicine.
FAU - Shen, Kai
AU  - Shen K
AD  - Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, 
      West China Hospital.
AD  - West China School of Medicine.
FAU - Hao, Jianqi
AU  - Hao J
AD  - West China School of Medicine.
FAU - Feng, Yuying
AU  - Feng Y
AD  - West China School of Medicine.
FAU - Yuan, Chi
AU  - Yuan C
AD  - West China School of Medicine.
FAU - Zhu, Yuqi
AU  - Zhu Y
AD  - West China School of Medicine.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, 
      West China Hospital.
AD  - West China School of Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Protein Kinase Inhibitors)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/chemically induced
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology/secondary
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Kidney Neoplasms/drug therapy/pathology/secondary
MH  - Male
MH  - Middle Aged
MH  - Perioperative Care/*standards
MH  - Progression-Free Survival
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/therapeutic use
MH  - Proteinuria/chemically induced
MH  - Sunitinib/administration & dosage/*adverse effects/*therapeutic use
MH  - Thrombocytopenia/chemically induced
PMC - PMC6531174
COIS- The authors declare no interest of conflict.
EDAT- 2019/05/18 06:00
MHDA- 2019/05/29 06:00
PMCR- 2019/05/17
CRDT- 2019/05/18 06:00
PHST- 2019/05/18 06:00 [entrez]
PHST- 2019/05/18 06:00 [pubmed]
PHST- 2019/05/29 06:00 [medline]
PHST- 2019/05/17 00:00 [pmc-release]
AID - 00005792-201905170-00009 [pii]
AID - MD-D-18-09282 [pii]
AID - 10.1097/MD.0000000000015424 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 May;98(20):e15424. doi: 10.1097/MD.0000000000015424.